<DOC>
	<DOCNO>NCT00822913</DOCNO>
	<brief_summary>The researcher investigate effectiveness safety BoNT/A inject detrusor muscle patient PD MSA detrusor muscle overactivity unresponsive conventional medical therapy .</brief_summary>
	<brief_title>Botulinum A Toxin Patients With Parkinson 's Disease</brief_title>
	<detailed_description>Patients include overactive bladder symptom refractory medical therapy . Other cause overactive bladder symptom include urogenital prolapse recurrent urinary tract infection exclude . None patient anticoagulant therapy drug interfere neuromuscular transmission . The study approve local ethical committee patient give inform consent . Patients inform possible need intermittent catheterization BoNT/A treatment . As outcome measure assess clinical urodynamic variable .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<criteria>Patients overactive bladder symptom refractory medical therapy . Other cause overactive bladder symptom include urogenital prolapse recurrent urinary tract infection exclude . Concomitant anticoagulant therapy drug interfere neuromuscular transmission . Neuromuscular disease like LambertEaton syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Botulinum A toxin</keyword>
	<keyword>Parkinson 's disease</keyword>
</DOC>